Skip to main content

Bruno Julianne's Form 4 filing

CRISPR Therapeutics AG (CRSP) · filed Mar 12, 2025

Accession no.
0000950170-25-038214
Filed
Mar 12, 2025
Trade date
Mar 10-12, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $59.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bruno JulianneCIK 0002019645Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 10, 2025Common SharesMOption exerciseAcquired+2,399––9,461Direct
Mar 11, 2025Common SharesSSaleDisposed−1,198$42.42−$50,819.168,263Direct
Mar 11, 2025Common SharesMOption exerciseAcquired+435––8,698Direct
Mar 12, 2025Common SharesSSaleDisposed−190$43.32−$8,230.88,508Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2025Common SharesMOption exerciseDisposed−2,399––4,796Direct
Mar 11, 2025Common SharesMOption exerciseDisposed−435––0Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)